They are associated with excess bone marrow blast proportion, thrombocytopenia, complex karyotypes, resistance and early relapse to lenalidomide, HMAs, and aHSCT, all of which result in miserable outcomes for MDS cases with TP53 mutations. This evidence concerns the gene TP53 and myelodysplastic syndrome.